EndoSystem mini-invasive treatment system for hypertrophic cardiomyopathy (HCM) is the national key research and development project, the mini-invasive treatment system for hypertrophic cardiomyopathy (HCM) has realized that, hypertrophic cardiomyopathy surgical treatment can be performed without thoracotomy, arrested-heart and blood transfusion, which has been supported by the Digital Diagnosis and Treatment special research and development Project of Ministry of Science and Technology of the People's Republic of China.

The HCM project has obtained 13 patents including Patent Cooperation Treaty (PCT) and China National invention patents, and relevant research results will be published in International authoritative journals in the near future.

The mini-invasive treatment system for hypertrophic cardiomyopathy has been applied clinically in TONGJI HOSPITAL AFFILIATED TO TONGJI MEDICAL COLLEGE HUST, with a success rate of 100%. It is expected to be marketed in China through innovative medical deveice green channel in the future and gradually promoted in clinical practice.